Professional Marketing: Novartis, Epocrates, Cegedim Dendrite and SK&A Information Services

Share this article:
Novartis launched schizophrenia med Fanapt to US physicians, following a May 2009 approval. In October, Novartis acquired US and Canadian commercialization rights to the pill from Vanda, which retains ex-US marketing rights. A long-acting injectable (depot) formulation is being developed.

Mobile clinical-software outfit Epocrates hired Geoffrey Rutledge, MD, PhD, as chief medical officer and EVP, product development. Rutledge, who has held senior-management roles with WebMD and First Consulting Group, will oversee Epocrates' medical-information team and lead the development of new products.

CRM firm Cegedim Dendrite acquired healthcare data provider SK&A Information Services for an undisclosed sum. SK&A maintains a telephone-verifiable database of contact records used by pharma clients for commercial planning and operations. The firm will be branded as SK&A, A Cegedim Company.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.